Ground breaking win for cancer patients
Published 31-JUL-2017 15:07 P.M.
1 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
As soon as tomorrow, lung and renal cancer patients will be able to get their hands on Opdivo.
Opdivo is a type of immunotherapy that differs from chemotherapy and other radiation treatments by activating the body’s immune system to combat cancer cells directly.
Until now, a one off treatment of Opdivo would cost A$5,000, or over A$100,000 per year. Thanks to the Federal Government, it will now be available for just A$38.80 per treatment, or A$6.30 with a concession card.
Unfortunately, lung cancer is one of the leading killers in Australia, claiming 8,000 lives per year. Opdivo’s addition to the PBS could lower that number significantly.
In clinical trials of the drug, tumours were partially or completely shrunk in 19% of patients, a seven percent increase over chemotherapy. Furthermore, patient’s risk of death was reduced by 27% over chemotherapy patients in the same trial.
“This drug changes and saves lives,” Health Minister Greg Hunt said on March 30, “for patients and their families it provides the precious gift of a full and healthy life”.
Hunt believes Opdivo’s addition to the Pharmaceutical Benefits Scheme (PBS) is a substantial development for cancer sufferers, “the most uplifting thing is to see breakthroughs that save lives, transform families and give people real hope – and that’s exactly what Opdivo does.”
Opdivo rose to prominence in the public arena after AFL star Jarryd Roughead credited it with saving his life.
Roughead suffered an aggressive return of melanoma which spread to his lungs in 2016. Amazingly he was cancer free just months later, “I’ve had a complete response to the treatment so far and (my doctor has) given me the all-clear to get back to living normally, to doing things I want — which is playing footy and living my life,” he said.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.